Clinical Trials
52 trialsCamrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Guangdong Association of Clinical Trials
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
Jiangsu HengRui Medicine Co., Ltd.
Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC
The First Hospital of Hebei Medical University
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
PASSION
Jiangsu HengRui Medicine Co., Ltd.
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Shanghai Shengdi Pharmaceutical Co., Ltd
A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Tongji University
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
Shandong Cancer Hospital and Institute
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Zhejiang Cancer Hospital
Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
CrystalGenomics, Inc.
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
Jiangsu HengRui Medicine Co., Ltd.
PANORAMA
Nanfang Hospital, Southern Medical University
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
Hunan Cancer Hospital
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
NSCLC
Henan Provincial People's Hospital
A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy
ChineseAMS
IMCORT-2
Sichuan Cancer Hospital and Research Institute
SABRE
Wuhan University
A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion
The First Affiliated Hospital of Zhengzhou University
CAMERA
Henan Cancer Hospital
MAGIC
Shanghai Pulmonary Hospital, Shanghai, China
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
Zhejiang Cancer Hospital
NEOSUN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
CAMFA-L
Shanghai Chest Hospital
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC
Beijing Chest Hospital
Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
F&C
Tianjin Medical University Cancer Institute and Hospital
A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
ChineseAMS
MWA in NSCLC
Shandong Provincial Hospital
Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy(Irinotecan Plus Platinum)and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer(SCLC)
Peking Union Medical College Hospital
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
The First Affiliated Hospital of Xiamen University
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
Peking University Cancer Hospital & Institute
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC
Shandong Cancer Hospital and Institute
CCA-MPLC
Guangzhou Institute of Respiratory Disease
Compass-001
Sun Yat-sen University
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
Sichuan Cancer Hospital and Research Institute
A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
Xuanwu Hospital, Beijing
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Henan Cancer Hospital